Sio Capital Management Holding in Sage Therapeutics (Put) (SAGE) Upped as Stock Rose; Companhia Brasileira De Dist (CBD) Shareholder Harding Loevner LP Boosted Position by $1.10 Million as Stock Rose

January 14, 2018 - By Dolores Ford

Sio Capital Management Llc increased its stake in Sage Therapeutics Inc (Put) (SAGE) by 217.33% based on its latest 2017Q3 regulatory filing with the SEC. Sio Capital Management Llc bought 130,400 shares as the company’s stock rose 0.86% with the market. The institutional investor held 190,400 shares of the health care company at the end of 2017Q3, valued at $11.86 million, up from 60,000 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in Sage Therapeutics Inc (Put) for a number of months, seems to be bullish on the $7.22 billion market cap company. The stock increased 0.72% or $1.26 during the last trading session, reaching $175.86. About 323,490 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since January 14, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

Harding Loevner Lp increased its stake in Companhia Brasileira De Dist (CBD) by 0.75% based on its latest 2017Q3 regulatory filing with the SEC. Harding Loevner Lp bought 47,850 shares as the company’s stock rose 11.69% with the market. The hedge fund held 6.47 million shares of the food chains company at the end of 2017Q3, valued at $153.06 million, up from 6.42M at the end of the previous reported quarter. Harding Loevner Lp who had been investing in Companhia Brasileira De Dist for a number of months, seems to be bullish on the $6.47 billion market cap company. The stock increased 0.69% or $0.16 during the last trading session, reaching $23.35. About 122,967 shares traded. Companhia Brasileira de Distribuição (NYSE:CBD) has risen 80.03% since January 14, 2017 and is uptrending. It has outperformed by 63.33% the S&P500.

Among 6 analysts covering Companhia Brasileira de Distribuicao (NYSE:CBD), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Companhia Brasileira de Distribuicao had 10 analyst reports since August 26, 2015 according to SRatingsIntel. The stock of Companhia Brasileira de Distribuição (NYSE:CBD) has “Underweight” rating given on Tuesday, October 13 by JP Morgan. JP Morgan upgraded Companhia Brasileira de Distribuição (NYSE:CBD) on Thursday, March 23 to “Overweight” rating. The stock has “Outperform” rating by Credit Suisse on Tuesday, November 7. The firm has “Hold” rating by HSBC given on Thursday, November 3. The firm has “Neutral” rating given on Monday, November 9 by Citigroup. The firm has “Neutral” rating given on Thursday, December 15 by Bank of America. The firm earned “Neutral” rating on Monday, November 9 by Nomura. On Friday, October 16 the stock rating was downgraded by Bank of America to “Underperform”.

Harding Loevner Lp, which manages about $36.30B and $17.58 billion US Long portfolio, decreased its stake in Paypal Hldgs Inc by 66,175 shares to 6.03 million shares, valued at $386.35 million in 2017Q3, according to the filing. It also reduced its holding in Pricesmart Inc (NASDAQ:PSMT) by 13,296 shares in the quarter, leaving it with 59,152 shares, and cut its stake in Amerisourcebergen Corp (NYSE:ABC).

Since December 14, 2017, it had 0 buys, and 1 insider sale for $9.57 million activity.

Sio Capital Management Llc, which manages about $116.75 million and $192.73M US Long portfolio, decreased its stake in Puma Biotechnology Inc (NYSE:PBYI) by 52,800 shares to 27,221 shares, valued at $3.26 million in 2017Q3, according to the filing. It also reduced its holding in Advanced Accelerator Applications Sa by 55,941 shares in the quarter, leaving it with 52,582 shares, and cut its stake in Steadymed Ltd.

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics had 51 analyst reports since September 3, 2015 according to SRatingsIntel. Stifel Nicolaus maintained it with “Buy” rating and $198.0 target in Thursday, December 7 report. H.C. Wainwright downgraded the shares of SAGE in report on Wednesday, February 22 to “Neutral” rating. Stifel Nicolaus initiated the shares of SAGE in report on Monday, November 14 with “Buy” rating. The stock has “Neutral” rating by Goldman Sachs on Wednesday, March 30. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Cowen & Co on Thursday, August 3. The firm earned “Buy” rating on Tuesday, September 12 by Needham. On Friday, August 4 the stock rating was maintained by H.C. Wainwright with “Hold”. The company was upgraded on Wednesday, December 14 by Raymond James. Stifel Nicolaus maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Tuesday, September 12. Stifel Nicolaus has “Buy” rating and $91.0 target. The company was maintained on Tuesday, September 12 by Canaccord Genuity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>